Loading...

PE/Cyanine7 anti-mouse CD8a Antibody

Pricing & Availability
Clone
53-6.7 (See other available formats)
Regulatory Status
RUO
Other Names
T8, Lyt2, Ly-2
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
53-67_PECyanine7_CD8a_Antibody_1_071124
C57BL/6 mouse splenocytes were stained with anti-mouse CD3ε (clone 145-2C11) FITC and anti-mouse CD8a (clone 53-6.7) PE/Cyanine7 (left) or rat IgG2a, κ PE/Cyanine7 isotype control (right).
  • 53-67_PECyanine7_CD8a_Antibody_1_071124
    C57BL/6 mouse splenocytes were stained with anti-mouse CD3ε (clone 145-2C11) FITC and anti-mouse CD8a (clone 53-6.7) PE/Cyanine7 (left) or rat IgG2a, κ PE/Cyanine7 isotype control (right).
Compare all formats See PE/Cyanine7 spectral data
Cat # Size Price Quantity Check Availability Save
100721 25 µg 55€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100722 100 µg 159€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE/Cyanine7 under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The CD8a antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is = 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).

Additional Product Notes

BioLegend is in the process of converting the name PE/Cy7 to PE/Cyanine7. The dye molecule remains the same, so you should expect the same quality and performance from our PE/Cyanine7 products. Please contact Technical Service if you have any questions.

Application References

(PubMed link indicates BioLegend citation)
  1. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP)
  2. Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete)
  3. Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP)
  4. Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Kamimura D, et al. 2006. J. Immunol. 177:306.
  9. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete)
  10. Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed
  11. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  12. Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed
  13. Lee CH, et al. 2009. Clin. Cancer Res. PubMed
  14. Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed
  15. Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed
  16. Guo Y, et al. 2008. Blood 112:480. PubMed
  17. Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed
  18. Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed
  19. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  20. Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed
  21. Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed
  22. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  23. Medyouf H, et al. 2010. Blood 115:1175. PubMed
  24. Riedl P, et al. 2009. J. Immunol. 183:370. PubMed
  25. Apte SH, et al. 2010. J. Immunol. 185:998. PubMed
  26. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  27. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  28. Cui L, et al. 2015. J Control Release. 206:220. PubMed
  29. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  30. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Calabrese DR, et al. 2020. J Clin Invest. . PubMed
  2. Jarick KJ, et al. 2018. Front Immunol. 9:1468. PubMed
  3. Seo JB, et al. 2019. Nat Metab. 1:86. PubMed
  4. Yu X, et al. 2020. Nat Commun. 11:1110. PubMed
  5. Zhu Z, et al. 2022. Clin Cancer Res. 28:4820. PubMed
  6. Sugitani N, et al. 2022. Cell Rep. 40:111371. PubMed
  7. Bajaj R, et al. 2022. Cell Rep. 40:111429. PubMed
  8. Axelrod ML, et al. 2022. Nature. 611:818. PubMed
  9. Gao L, et al. 2023. J Nanobiotechnology. 21:56. PubMed
  10. Schönberger K, et al. 2023. Anal Chem. 95:4325. PubMed
  11. Li L, et al. 2023. iScience. 26:106095. PubMed
  12. Liu N, et al. 2023. Cell Death Dis. 14:170. PubMed
  13. Cheng K, et al. 2023. Small. 19:e2300125. PubMed
  14. Li G, et al. 2023. Cell Death Dis. 14:185. PubMed
  15. Guo D, et al. 2023. Cell Biosci. 13:51. PubMed
  16. Wang Y, et al. 2023. Front Bioeng Biotechnol. 11:1128268. PubMed
  17. Huang T, et al. 2023. Front Immunol. 14:1124152. PubMed
  18. Sun R, et al. 2023. PLoS One. 18:e0282722. PubMed
  19. Xie J, et al. 2023. Mol Ther Oncolytics. 29:61. PubMed
  20. Vella JL, et al. 2021. Life Sci Alliance. 4:. PubMed
  21. Vick SC, et al. 2021. J Immunol. 207:2598. PubMed
  22. Li H, et al. 2022. Cancer Cell. 40:36. PubMed
  23. Xin B, et al. 2022. Hepatology. 76:630. PubMed
  24. Schnell A, et al. 2021. Cell. 184:6281. PubMed
  25. Fu A, et al. 2022. Cell. 185:1356. PubMed
  26. Chakraborty P, et al. 2022. Cancer Res. 82:1969. PubMed
  27. Guttman O, et al. 2022. J Cell Biol. 221: . PubMed
  28. Zhu J, et al. 2022. Research (Wash D C). 2022:9816272. PubMed
  29. Poh AR, et al. 2022. Cell Rep. 41:111479. PubMed
  30. Gao Y, et al. 2022. Cell Res. 32:1086. PubMed
  31. Chen X, et al. 2022. J Extracell Vesicles. 11:e12279. PubMed
  32. Yang H, et al. 2023. Cell Death Differ. 30:560. PubMed
  33. Horkova V, et al. 2023. Nat Immunol. 24:174. PubMed
  34. Roh YJ, et al. 2023. Lab Anim Res. 39:2. PubMed
  35. Giannou AD, et al. 2023. Immunity. 56:125. PubMed
  36. Briukhovetska D, et al. 2023. Immunity. 56:143. PubMed
  37. Wang C, et al. 2023. Exp Mol Med. 55:347. PubMed
  38. Wang J, et al. 2023. Inflamm Regen. 43:12. PubMed
  39. Georgiev GI, et al. 2022. Cell Chem Biol. 29:811. PubMed
  40. Lechuga-Vieco AV, et al. 2020. Sci Adv. 6:eaba5345. PubMed
  41. Chappaz S, et al. 2021. Cell Reports. 36(3):109430. PubMed
  42. Garcia-Fabiani MB, et al. 2020. Methods Enzymol. 632:369. PubMed
  43. Marco Barros R, et al. 2016. Cell. 167: 203-218. PubMed
  44. Wu N, et al. 2020. Cell Rep. 30:1129. PubMed
  45. Alissafi T, et al. 2018. J Clin Invest. 128:3840. PubMed
  46. Tello‐Lafoz M, et al. 2017. Sci Rep. . 10.1038/s41598-017-16370-w. PubMed
  47. Denk D, et al. 2022. Immunity. 55:2059. PubMed
  48. Schönberger K, et al. 2022. Cell Stem Cell. 29:131. PubMed
  49. Ferrere G, et al. 2021. JCI Insight. 6:. PubMed
  50. Li X, et al. 2022. Nat Commun. 13:2794. PubMed
  51. Zhang R, et al. 2021. Cell Mol Immunol. 18:1222. PubMed
  52. Ma F, et al. 2020. Cell Death Dis. 1.172222222. PubMed
  53. Baram T, et al. 2021. Cells. 10:. PubMed
  54. Piepke M, et al. 2021. J Neuroinflammation. 18:265. PubMed
  55. Luo R, et al. 2021. Theranostics. 11:117. PubMed
  56. Hu J, et al. 2021. Sci Adv. 7:. PubMed
  57. Mei S, et al. 2022. Front Immunol. 13:911164. PubMed
  58. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  59. Plumlee CR, et al. 2020. Cell Host Microbe. 29(1):68-82.e5. PubMed
  60. Wu FTH, et al. 2019. Br J Cancer. 120:196. PubMed
  61. Chow MT et al. 2019. Immunity. 50(6):1498-1512 . PubMed
  62. Zhao J, et al. 2019. Nat Commun. 10:899. PubMed
  63. Bowers E, et al. 2018. Nat Med. 24:95. PubMed
  64. Leier A, et al. 2022. Mol Ther Nucleic Acids. 28:261. PubMed
  65. Andreas N, et al. 2021. Arthritis Res Ther. 23:222. PubMed
  66. Alotaibi F, et al. 2021. Front Immunol. 11:584937. PubMed
  67. Snyder LM, et al. 2021. PLoS Pathog. 17:e1009970. PubMed
  68. del Rio ML, et al. 2021. Transl Res. Online ahead of print.. PubMed
  69. Chen WS, et al. 2021. Cell Rep. 37:109974. PubMed
  70. Tan X, et al. 2021. Front Oncol. 11:768222. PubMed
  71. Ma C, et al. 2021. Signal Transduct Target Ther. 6:353. PubMed
  72. Saito S, et al. 2020. Nutrients. 12:. PubMed
  73. Neubert K, et al. 2014. J Immunol. 192:5830. PubMed
  74. Sakthivel P, et al. 2014. PLoS One. 9:100970. PubMed
  75. Starkl P, et al. 2020. Immunity. 53(4):793-804.e9. PubMed
  76. Peng Z, et al. 2021. STAR Protocols. 2(2):100595. PubMed
  77. Okuniewska M, et al. 2021. Cell Reports. 36(2):109368. PubMed
  78. Zhao B, et al. 2021. Cell Reports. 36(3):109401. PubMed
  79. Pan H, et al. 2020. Mol Psychiatry. . PubMed
  80. Brooks JF, et al. 2020. Cytotherapy. 22:436. PubMed
  81. Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed
  82. Hung PJ, et al. 2018. Mol Cell. 71:332. PubMed
  83. Cai B, et al. 2021. Mol Cancer. 20:165. PubMed
  84. Papafragkos I, et al. 2022. Front Immunol. 13:889075. PubMed
  85. Perner C, et al. 2020. Immunity. 53(5):1063-1077.e7. PubMed
  86. Yi M, et al. 2021. J Hematol Oncol. 14:27. PubMed
  87. Guo Z, et al. 2016. Nat Commun. 7:10307. PubMed
  88. Shade K, et al. 2015. J Exp Med. 212:457. PubMed
  89. Liu J, et al. 2012. PLoS One. 7:e44044. PubMed
  90. Nakamura‐Ishizu A et al. 2018. Cell reports. 25(7):1772-1785 . PubMed
  91. Guo HF, et al. 2021. Commun Biol. 4:482. PubMed
  92. Wei M, et al. 2014. Protein Eng Des Sel. 27:289. PubMed
  93. Collinson-Pautz M, et al. 2016. PLoS One. 11:e0164547. PubMed
  94. Amor C, et al. 2020. Nature. 583:127. PubMed
  95. Dumas AA, et al. 2020. EMBO J. 39:e103790. PubMed
  96. Szafran BN, et al. 2021. Chemical Research in Toxicology. 34(6):1556-1571. PubMed
  97. Li J, et al. 2020. Cancer Discov. . PubMed
  98. Wei SC, et al. 2020. Cancer Discov. . PubMed
  99. He W et al. 2018. Immunity. 49(6):1175-1190 . PubMed
  100. Liu H, et al. 2020. Cancer Cell. 37(3):324-339. PubMed
  101. Marchingo JM, et al. 2020. eLife. 9:e53725.. PubMed
  102. Alsaleh G, et al. 2020. Elife. 9: . PubMed
  103. Cheng K, et al. 2021. Nat Commun. 12:2041. PubMed
  104. Yang K, et al. 2022. J Clin Invest. 132:. PubMed
  105. Zebley CC, et al. 2021. Cell Rep. 37:109796. PubMed
  106. Dane EL, et al. 2022. Nat Mater. 21:710. PubMed
  107. Guo W, et al. 2022. J Immunother Cancer. 10:. PubMed
  108. Zhao F, et al. 2022. Front Immunol. 13:873720. PubMed
  109. Wang Y, et al. 2021. Sci Rep. 1.429861111. PubMed
  110. Li J, et al. 2020. Cancer Immunol Res. 0.529166667. PubMed
  111. Köchl R, et al. 2020. Elife. 9:00. PubMed
  112. Sullivan B, et al. 2015. PLoS Pathog. 11:1004588. PubMed
  113. Yang S, et al. 2019. Nat Commun. 10:2782. PubMed
  114. Wang GZ, et al. 2019. Nat Commun. 10:1125. PubMed
  115. Dar HY, et al. 2018. Sci Rep. 8:2503. PubMed
  116. Daniel CJ, et al. 2022. Mol Cancer Res. 20:1151. PubMed
  117. Sodji QH, et al. 2022. Cancer Res Commun. 2:725. PubMed
  118. Mehta AK, et al. 2021. Nat Cancer. 2:66. PubMed
  119. Lehmann M, et al. 2016. J Leukoc Biol. 99: 1057 - 1064. PubMed
  120. Walter F, et al. 2020. PLoS One. 15:e0239369. PubMed
  121. Gong Y, et al. 2020. Cell Metabolism. 33(1):51-64.e9. PubMed
  122. Dar HY, et al. 2018. Bone Rep. 8:46. PubMed
  123. Dietmar Herndler‐Brandstetter et al. 2018. Immunity. 48(4):716-729 . PubMed
  124. Yue X, et al. 2019. Nat Commun. 10:2011. PubMed
  125. Li J, et al. 2018. Immunity. 49:178. PubMed
  126. Domingo–Gonzalez R, et al. 2020. eLife. 9:e56890.. PubMed
  127. Lu Y, et al. 2021. Gastroenterology. 161:575. PubMed
  128. Taniguchi H, et al. 2022. Cell Rep. 39:110814. PubMed
  129. Progatzky F, et al. 2021. Nature. 599:125. PubMed
  130. Akazawa S, et al. 2021. Diabetologia. 64:878. PubMed
  131. Chin AL, et al. 2021. Nat Commun. 12:5138. PubMed
  132. Mulas F, et al. 2020. Cell Mol Immunol. . PubMed
  133. Wen Y, et al. 2020. Hypertension. 869:75. PubMed
  134. Qi S et al. 2016. eLife. 5 pii: e14756. PubMed
  135. Pinho S, et al. 2022. Nat Cell Biol. 24:290. PubMed
  136. , et al. 2021. Eur J Immunol. 51:2708. PubMed
  137. Zeng Q, et al. 2022. Front Immunol. 13:740805. PubMed
  138. Reese B, et al. 2020. J Immunol. 205:3218. PubMed
  139. Abramowski P, et al. 2014. J Neuroimmunol. 274:111. PubMed
  140. Ariyoshi Y, et al. 2016. Gene Ther. 10.1038/gt.2016.7. PubMed
  141. Deerhake ME, et al. 2021. Immunity. 54(3):484-498.e8. PubMed
  142. Vaena S, et al. 2021. Cell Reports. 35(5):109076. PubMed
  143. Zhang H, et al. 2019. Mol Cell. 76:110. PubMed
  144. Cheng Y, et al. 2019. Clin Cancer Res. 25:2621. PubMed
  145. Pietronigro E, et al. 2019. Sci Rep. 9:12055. PubMed
  146. Liang J, et al. 2020. Sci Adv. 6:eabc3646. PubMed
  147. Tan X, et al. 2021. Sci Adv. 7: . PubMed
  148. Sapra L, et al. 2021. Sci Rep. 11:1807. PubMed
  149. Alameh MG, et al. 2021. Immunity. 54:2877. PubMed
  150. Jorapur A, et al. 2022. PLoS Pathog. 18:e1010200. PubMed
  151. Yang Y, et al. 2022. Elife. 11:. PubMed
  152. Kim S, et al. 2021. Elife. 10:. PubMed
  153. Anger-Góra N, et al. 2021. Oncol Lett. 22:582. PubMed
  154. Li H, et al. 2021. Adv Sci (Weinh). 2001596:8. PubMed
  155. Kyburz A, et al. 2019. J Allergy Clin Immunol. 143:1496. PubMed
  156. Yu X, et al. 2019. Nat Commun. 10:574. PubMed
  157. Chatterjee S et al. 2017. Cell metabolism. 27(1):85-100 . PubMed
  158. Xiao L, et al. 2021. Clin Cancer Res. 27:4338. PubMed
  159. Ding P, et al. 2022. Bone Res. 10:42. PubMed
  160. Lang V, et al. 2021. Elife. 10:. PubMed
  161. Yabas M, et al. 2016. PLoS One. 11: 0146774. PubMed
  162. Timilshina M, et al. 2017. PLoS One. 10.1371/journal.pone.0168942. PubMed
  163. Jandke A, et al. 2020. Nat Commun. 3.075694444. PubMed
  164. Wei Z, et al. 2021. Nat Commun. 0.805555556. PubMed
  165. Chulpanova DS, et al. 2021. Biology (Basel). 10:. PubMed
  166. Xu Q, et al. 2021. Theranostics. 11:1937. PubMed
  167. Niderla-Bielinska J, et al. 2021. Int J Mol Sci. :22. PubMed
  168. Chen R, et al. 2021. Cell Reports. 34(7):108751. PubMed
  169. Itoga M, et al. 2015. PLoS One. 10: e0123210. PubMed
  170. Kalafati L, et al. 2020. Cell. 183:771. PubMed
  171. Muri J, et al. 2020. eLife. 9:e53627.. PubMed
  172. He J, et al. 2020. Evid Based Complement Alternat Med. 2020:5637507. PubMed
  173. Yuan X, et al. 2017. Elife. 6:e29540. PubMed
  174. Nelson CE et al. 2019. Cell Rep. 28(12):3092-3104 . PubMed
  175. Hsu M, et al. 2022. Nat Immunol. 23:581. PubMed
  176. Sakamoto K, et al. 2021. Immunity. 54:2321. PubMed
  177. Zhang S, et al. 2022. Nat Commun. 13:4744. PubMed
  178. Robertson TF, et al. 2021. J Cell Biol. 220:. PubMed
  179. X X, et al. 2016. J Immunol . 197: 1683-1691. PubMed
  180. Gomzikova MO, et al. 2020. Pharmaceutics. 12:00. PubMed
  181. Ligon MM, et al. 2020. Mucosal Immunol. 1.172222222. PubMed
  182. Yu M, et al. 2021. Molecular Cell. 81(6):1216-1230.e9. PubMed
  183. Wedekind MF, et al. 2021. iScience. 24(7):102759. PubMed
  184. Emily A Thompson et al. 2019. Cell reports. 26(11):2859-2867 . PubMed
  185. Oliveira AC et al. 2017. eLife. 6 pii: e30883. PubMed
  186. Zhang X, et al. 2021. Nat Commun. 12:4536. PubMed
  187. Bhatt D, et al. 2021. J Exp Med. 218:. PubMed
  188. Wang D, et al. 2022. EMBO Rep. 23:e53691. PubMed
  189. Schönberger K, et al. 2022. STAR Protoc. 3:101408. PubMed
  190. Kojima H, et al. 2021. Scand J Immunol. 93:e13020. PubMed
  191. Abdelsamed HA, et al. 2020. Nat Immunol. 1.276388889. PubMed
  192. Sebina I, et al. 2016. PLoS Pathog. 12:e1005999. PubMed
  193. Baglaenko Y, et al. 2016. PLoS One. 11: 0150515. PubMed
  194. Silva DA, et al. 2019. Nature. 565:186. PubMed
  195. Lee YS, et al. 2019. Sci Adv. 5:eaaw4176. PubMed
  196. Chen Y, et al. 2022. Nat Commun. 13:4468. PubMed
  197. Bell CR, et al. 2022. Nat Commun. 13:2063. PubMed
  198. Xiao Y, et al. 2021. Cell. 184:6037. PubMed
  199. Hoechst B, et al. 2016. J Immunol. 195:1517-1523. PubMed
  200. Yoshida H, et al. 2019. Cell. 176:897. PubMed
  201. Chao JL, et al. 2021. Cell Rep Med. 2:100399. PubMed
  202. Rouse MD, et al. 2020. Front Microbiol. 11:414. PubMed
  203. Lopes N, et al. 2022. Elife. 11:. PubMed
  204. Tang S, et al. 2022. Virol J. 19:32. PubMed
  205. Pantelidou C, et al. 2022. NPJ Breast Cancer. 8:102. PubMed
  206. Fitzpatrick Z, et al. 2020. Nature. 587:472. PubMed
  207. Liu Q, et al. 2021. Adv Mater. 33:e2102852. PubMed
  208. Sharma R, et al. 2021. J Neuroinflammation. 72:18. PubMed
  209. Bonavita E, et al. 2020. Immunity. 1215:53. PubMed
  210. Siolas D, et al. 2021. Cell Reports. 36:109578. PubMed
  211. Sheng J, et al. 2021. eLife. 10:00. PubMed
  212. Mykkänen O, et al. 2014. PLoS One. 9:114790. PubMed
  213. Chakraborty P, et al. 2020. Cell Reports. 28(7):1879-1893.e7.. PubMed
  214. Ding Z, et al. 2017. Sci Rep. 10.1038/s41598-017-12488-z. PubMed
  215. Chryplewicz A, et al. 2022. Cancer Cell. 40:1111. PubMed
  216. Lau P, et al. 2022. Cell Mol Immunol. :. PubMed
  217. Xiao Z, et al. 2022. Mater Today Bio. 15:100297. PubMed
  218. Schmit T, et al. 2022. Cell Rep. 38:110456. PubMed
  219. Wang X, et al. 2022. Elife. 11:. PubMed
  220. Endo-Umeda K, et al. 2021. Sci Rep. 11:22595. PubMed
  221. Liu X, et al. 2021. Adv Sci (Weinh). 8:e2100233. PubMed
  222. Goc J, et al. 2021. Cell. 184:5015. PubMed
  223. Timilshina M, et al. 2020. Cell Reports. 27(10):2948-2961.e7.. PubMed
  224. Lai NY, et al. 2020. Cell. 180:33:00. PubMed
  225. Wang X, et al. 2021. Sci Transl Med. 13:. PubMed
  226. Goubet AG, et al. 2021. Cell Death Differ. 28:2276. PubMed
  227. Petty AJ, et al. 2021. JCI Insight. 6:. PubMed
  228. Avgustinova A, et al. 2021. Cell Stem Cell. . PubMed
  229. Ye Y, et al. 2020. Genome Med. 0.557638889. PubMed
  230. Kim SH, et al. 2020. Neoplasia. 1.3375. PubMed
  231. Reinke S, et al. 2020. Cell Reports. 30(8):2501-2511. PubMed
  232. Brenner E, et al. 2020. Nat Commun. 11:1335. PubMed
  233. Tan DQ, et al. 2019. Cell Rep. 26:2316. PubMed
  234. Yáñez A et al. 2017. Immunity. 47(5):890-902 . PubMed
  235. Chen S, et al. 2018. Nat Commun. 9:5298. PubMed
  236. Aurélien Trompette et al. 2018. Immunity. 48(5):992-1005 . PubMed
  237. Plaza-Sirvent C, et al. 2021. Front Immunol. 12:705436. PubMed
  238. Fearon AE, et al. 2021. iScience. 24:103143. PubMed
  239. Lal JC, et al. 2021. Breast Cancer Res. 23:83. PubMed
  240. Aggarwal N, et al. 2021. Cell Rep. 37:110170. PubMed
RRID
AB_312760 (BioLegend Cat. No. 100721)
AB_312761 (BioLegend Cat. No. 100722)

Antigen Details

Structure
Ig superfamily, CD8α chain, 34 kD
Distribution

Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells

Function
Co-receptor for TCR
Ligand/Receptor
MHC class I molecule
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Zamoyska R. 1994. Immunity 1:243.
3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.

Gene ID
12525 View all products for this Gene ID
UniProt
View information about CD8alpha on UniProt.org

Other Formats

View All CD8a Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD8a 53-6.7 FC
Biotin anti-mouse CD8a 53-6.7 FC,IHC
FITC anti-mouse CD8a 53-6.7 FC
PE anti-mouse CD8a 53-6.7 FC
PE/Cyanine5 anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC-F,IP
PE/Cyanine7 anti-mouse CD8a 53-6.7 FC
APC/Cyanine7 anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 488 anti-mouse CD8a 53-6.7 FC,3D IHC
Alexa Fluor® 647 anti-mouse CD8a 53-6.7 FC,IHC-F,3D IHC,SB
Pacific Blue™ anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 700 anti-mouse CD8a 53-6.7 FC
PerCP/Cyanine5.5 anti-mouse CD8a 53-6.7 FC
PerCP anti-mouse CD8a 53-6.7 FC
Brilliant Violet 421™ anti-mouse CD8a 53-6.7 FC,IHC,SB
Brilliant Violet 570™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 650™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 605™ anti-mouse CD8a 53-6.7 FC
Ultra-LEAF™ Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC,IP,Depletion,Block
Brilliant Violet 711™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 785™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 510™ anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a (Maxpar® Ready) 53-6.7 FC,CyTOF®
Alexa Fluor® 594 anti-mouse CD8a 53-6.7 IHC-F,FC,3D IHC
PE/Dazzle™ 594 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 750 anti-mouse CD8a 53-6.7 FC
GoInVivo™ Purified anti-mouse CD8a 53-6.7 FC
TotalSeq™-A0002 anti-mouse CD8a 53-6.7 PG
Spark Blue™ 550 anti-mouse CD8a 53-6.7 FC
Spark NIR™ 685 anti-mouse CD8a 53-6.7 FC
TotalSeq™-C0002 anti-mouse CD8a 53-6.7 PG
TotalSeq™-B0002 anti-mouse CD8a 53-6.7 PG
Spark YG™ 570 anti-mouse CD8a 53-6.7 IHC-F
PE/Fire™ 640 anti-mouse CD8a 53-6.7 FC
PE/Fire™ 700 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 574 anti-mouse CD8a Antibody 53-6.7 FC
Spark Violet™ 423 anti-mouse CD8a Antibody 53-6.7 FC
Spark UV™ 387 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 515 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark Red™ 718 anti-mouse CD8a (Flexi-Fluor™) 53-6.7 FC
PE/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark PLUS UV™ 395 anti-mouse CD8a 53-6.7 FC
Go To Top Version: 2    Revision Date: 01.21.2014

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account